This page contains affiliate links. We may earn a commission at no extra cost to you.
$249–$349
The AVACEN 100 (Advanced Vascular Circulation Enhancement) is an FDA-cleared device that applies gentle heat and low negative pressure to the palm of the hand to warm blood in the thenar arteriovenous anastomoses (AVAs) — specialized blood vessels in the palm that can rapidly transfer heat to the systemic circulation. The clinical hypothesis is that warming blood through this palmar route increases systemic microvascular blood flow, which may improve nutrient and oxygen delivery to peripheral nerve tissue throughout the body. The device has FDA 510(k) clearance for temporary relief of pain associated with fibromyalgia and minor muscle pain. While evidence specific to peripheral neuropathy is limited, the mechanism — improving systemic microvascular circulation — is directly relevant to the vascular component of neuropathy, particularly diabetic neuropathy where peripheral microvascular insufficiency is a core pathological driver. The AVACEN is a lower-risk, non-invasive device that some integrative medicine clinics include in neuropathy protocols. Discuss with your physician before use if you have high blood pressure or cardiovascular conditions.
How It Works
The thenar arteriovenous anastomoses (AVAs) in the palm are specialized large-caliber shunt vessels that bypass the standard capillary bed — connecting arterioles directly to venules. These AVAs are found densely in the palms, soles, lips, and ears, and are the mechanism by which the body rapidly dissipates core body heat. When the AVACEN device applies mild warmth (approximately 104°F) and gentle negative pressure to the palm, blood flows preferentially through the dilated thenar AVAs, warming rapidly and returning to the systemic circulation.
The device’s hypothesis is that this warmed, AVA-routed blood raises systemic microvascular temperature slightly, triggering vasodilation throughout the peripheral microvascular network — the small arterioles and capillaries that supply nerve tissue, muscles, and skin. This systemic mild vasodilation would improve blood flow to peripheral nerve tissue throughout the body — an attractive mechanism for neuropathy conditions where microvascular ischemia is a pathological driver. Published physiological studies have confirmed that AVACEN use increases peripheral blood flow and skin temperature in distal extremities.
Evidence Base
AVACEN’s FDA clearance is for fibromyalgia-related pain and minor muscle pain, supported by clinical studies submitted for 510(k) clearance. A 2019 study published in the Journal of Pain Research found that AVACEN treatment significantly reduced pain scores and improved quality of life in fibromyalgia patients over 4 weeks compared to sham treatment. Peripheral blood flow improvement has been documented in published physiological studies.
For peripheral neuropathy specifically, published controlled trial evidence is limited. Clinical case series and patient-reported outcomes from integrative medicine practices suggest benefit in some neuropathy patients, particularly those with circulatory-component neuropathy. The physiological rationale — improving systemic microvascular flow — is aligned with neuropathy pathophysiology, but direct controlled evidence in neuropathy populations is needed before the device can be recommended as an evidence-established neuropathy treatment.
How Sessions Work
AVACEN sessions take 30 minutes and are performed seated, with the hand resting inside the device’s heated negative-pressure chamber. The device is quiet and passive — no active effort is required from the user during the session. Most patients find sessions comfortable and relaxing. Typical protocols suggest 1 to 2 sessions per day during an initial treatment course, followed by maintenance sessions as needed based on symptom response.
Results are generally not immediate — the cumulative effect on microvascular tone and circulation develops over repeated sessions. Most clinical protocols assess response at 4 to 6 weeks of consistent use. Some patients report warmth and improved circulation in their feet and lower legs during and immediately following AVACEN sessions, consistent with the device’s intended mechanism of action.
Pros
- FDA-cleared for pain relief — regulatory credibility
- Passive, comfortable 30-minute sessions — no effort or position requirement
- Systemic microvascular circulation improvement relevant to neuropathy pathophysiology
- Non-invasive with mild risk profile
- Evidence in fibromyalgia — a condition with overlapping pain mechanisms to neuropathy
Cons
- Limited controlled trial evidence specifically in peripheral neuropathy
- Higher device cost ($249–$349) relative to evidence base in neuropathy
- Mechanism is indirect — palm warming → systemic circulation → peripheral nerve perfusion
- Requires consistent daily use over weeks to assess response
- Not appropriate for patients with heart failure or severe hypertension without physician clearance
Frequently Asked Questions
Is the AVACEN covered by insurance for neuropathy?
Coverage for AVACEN is limited. It is FDA-cleared for fibromyalgia and minor muscle pain — neuropathy is not a labeled indication. Most insurers require FDA-labeled indications for coverage. Out-of-pocket pricing of $249–$349 is moderate for a durable medical device. Some HSA/FSA accounts may cover FDA-cleared therapeutic devices — verify with your plan administrator.
Can the AVACEN be used alongside TENS and infrared therapy for neuropathy?
Yes — the AVACEN operates through systemic circulatory mechanisms while TENS and infrared therapy work locally. There is no known conflict or interaction between these approaches. Many integrative neuropathy programs combine multiple modalities targeting different aspects of the condition. A reasonable protocol might use AVACEN for systemic circulation improvement, infrared foot wrap for local plantar tissue, and TENS for direct pain signal modulation.
Who should not use the AVACEN device?
Patients with uncontrolled hypertension, active Raynaud’s phenomenon, open hand wounds, severe peripheral artery disease of the upper extremity, or implanted electronic devices in the hand or forearm should discuss AVACEN use with their physician before starting. The device is contraindicated for use over implanted metal hardware in the hand or wrist. Pregnant women should not use the device.